Skip to content

INC

Incanthera plc

Apex


ISIN

GB00BGL7YW15

Bid

23.00

Mid

24.50

Ask

26.00

Key Information

Price Change
0.00%
Year High
27.50
Year Low
6.00
Last Trade
21 Jun 24
Market Cap
£28.59M
Par
0.02
Bid
23.00
Mid Price
24.50
Ask
26.00
Instrument Type
Ordinary Shares
MIFID Status
MTF
Tradable Securities
116.7M
Sector
Healthcare

Prices in GBX except for Market Cap in GBP

About Incanthera plc

Incanthera is a UK-based, dermatology and oncology therapeutics company focusing on discovery and development of targeted solutions. The Company has developed sophisticated formulation and targeting technology platforms to address previously unavailable options across dermatology and oncology. These deliver treatments specifically to a required site, enabling effective ingredients with precision targeting for optimal efficacy. Identifying and developing innovative solutions to current clinical, commercially relevant unmet needs, Incanthera combines new technology from industry and leading academics, as well as its in-house development team, with its unique targeting delivery platform. Current Focus: Incanthera’s Skincare Range The Company's current focus is a range of dermatological applications to meet currently unmet needs in the skincare market. Skin + CELL, Incanthera’s unique luxury skincare brand, brings scientifically proven formulations to cosmetics. Enriched with targeted bioactive B3 (an activated form of niacinamide) Skin + CELL’s unique formulations are delivered directly into the skin’s cells to optimise and protect cellular health, energy and protective capabilities. In December 2023, Incanthera announced a commercial skincare deal with Marionnaud Switzerland and Austria (“Marionnaud”), part of the world’s largest health, beauty and lifestyle retailer, A.S. Watson Group for the launch and distribution of Skin + CELL in a planned roll out across Marionnaud’s European store portfolio and subsequent launch across A.S. Watson’s remaining global territories, numbering over 16,000 stores. The Company originated from the Institute of Cancer Therapeutics, University of Bradford and has a portfolio of specific cancer-targeting therapeutics through a pipeline agreement with the Institute of Cancer Therapeutics and other corporate acquisitions. Incanthera’s strategy is to develop or acquire each asset, technology and candidate in its portfolio from initial acquisition or discovery to securing its future through commercially valuable partnerships at the earliest opportunity in its development pathway.

Incanthera plcApex

Today's Trading

VolumeNumber TradesValue Trades (GBP )
000.00

Latest Trades

DateVolumePrice (GBX)Value (GBP)

21 Jun 24

12:19

5,80023.601,368.79

21 Jun 24

10:49

10,00024.002,400.00

21 Jun 24

10:05

1,18524.60291.51

20 Jun 24

15:17

10,00024.002,400.00

20 Jun 24

14:15

94425.20237.89
View all trades

Latest Announcements & Notices

DateTitle
No announcements or notices
View all announcementsView all notices

Address

Registered Address

76 King Street, Manchester, M2 4NH, United Kingdom

Email

suzanne.brocks@incanthera.com

Phone

+44 (0) 161 817 5005

Contacts

Corporate Adviser

Cairn Financial Advisers LLP., 9th Floor, 107 Cheapside, London, EC2V 6DN, United Kingdom

Registrar

Neville Registrars Limited , Neville House,Steelpark Road, Halesowen, West Midlands, B62 8HD, United Kingdom
Loading...

Company

  • About
  • News
  • Investor Relations
  • Contact
  • Careers

© Aquis Exchange 2024. All rights reserved.

Terms & ConditionsPrivacy PolicyModern Slavery & Human Trafficking Policy
System statusnormal